More stem cell progress in stroke as Neuralstem gets Chinese trial go-ahead
This article was originally published in Scrip
China has strengthened its reputation as a location conducive to stem cell research by granting regulatory approval to a clinical trial for a regenerative therapy developed by the US firm Neuralstem, for motor deficits due to ischaemic stroke.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.